Please assess the completion status of the following clinical trial:

Trial Title: Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Letter of consent and release signed by each patient~* Body mass index: 25-34.99 kg/m2~* Body weight without variations above or under 5% during the three months prior to the study~* Diagnostic of metabolic syndrome according to the modified International Diabetes Federation definition: Central obesity (defined as waist circumference ≥ 80 cm in women and ≥ 90 cm in men)~Plus any two of the following four factors:~* Triglycerides: 150-499 mg/dL.~* High density lipoprotein: Woman \< 50 mg/dL, man \< 40 mg/dL.~* Blood pressure systolic:130-139 mmHg and/or Blood pressure diastolic: 85-89 mmHg~* Fasting glucose: 100-125 mg/dL~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Previous pharmacological treatment for components of metabolic syndrome~* Mental or physical illness interfering with the study~* Thyroid or cardiovascular disease~* Pregnant or suspected pregnant women~* Woman breastfeeding~* Index of body mass: ≥ 35 kg/m2~* Treatments known to affect metabolism of glucose, fats and affecting arterial tension~* Patients with hepatic or renal diseases background~* Patients diagnosed with kidneys disease~* Calcined magnesium intolerance~* Gymnema Sylvestre intolerance

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
- Gymnema Sylvestre (Type: EXPERIMENTAL): 600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).